Community immunity

Vaccines

Volumn , Issue , 2008, Pages 1573-1592

  Fine, Paul E M ^a   Mulholland, Kim ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85159015146     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50075-1     Document Type: Chapter

References (152)

1. PEM Fine (1993) Herd immunity: history, theory, practice. Epidemiol Rev 15 265-302.
2. JP Fox, L Elveback, W Scott, et al. (1971) Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 94 179-189.
3. RM Anderson (1992) The concept of herd immunity and the design of community-based immunization programmes. Vaccine 10 928-935.
4. E Jenner (1801) The Origin of the Vaccine Inoculation London: Shury
5. R Dubos and J Dubos (1953) The White Plague London: Victor Gollancz
6. DA Salmon, SP Teret, CR Macintyre, et al. (2006) Compulsory vaccination and conscientious or philosophical exemptions: past present and future. Lancet 367 436-442.
7. W Farr (1840) Second Annual Report of the Registrar-General of Births, Deaths, and Marriages in England London: Her Majesty's Stationery Office
8. WWC Topley and GS Wilson (1923) The spread of bacterial infection: the problem of herd immunity. J Hyg 21 243-249.
9. M Greenwood (1935) Epidemics and Crowd Diseases London: Williams & Norgate Ltd
10. WR Dowdle and DR Hopkins (Eds) (1998) The Eradication of Infectious Diseases Chichester, UK: John Wiley
11. WH Hamer (1906) Epidemic disease in England-the evidence of variability and of persistency of type. Lancet 1 733-739.
12. RM Anderson and RM May (1991) Infectious Diseases of Humans: Dynamics and Control Oxford, UK: Oxford University Press
13. G Macdonald (1957) The Epidemiology and Control of Malaria London: Oxford University Press
14. K Dietz (1993) The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res 2 23-41.
15. HW Hethcote (1983) Measles and rubella in the United States. Am J Epidemiol 117 2-13.
16. K Dietz (1975) Transmission and control of arbovirus diseases. D Ludwig, KL Cooke (Eds) Epidemiology Philadelphia: Society for Industrial and Applied Mathematics 104-121.
17. D Schenzle (1984) An age-structured model of pre- and post-vaccination measles transmission. IMA J Math Appl Med Biol 1 169-191.
18. PEM Fine (2003) The interval between successive cases of an infectious disease. Am J Epidemiol 158 1039-1047.
19. CE Mills, JM Robins and M Lipsitch (2004) Transmissibility of 1918 pandemic influenza. Nature 432 904-906.
20. NM Ferguson, DA Cummings, S Cauchemez, et al. (2005) Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437 209-214.
21. RM Anderson and RM May (1985) Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hyg (Camb) 94 365-436.
22. W Katzmann and K Dietz (1984) Evaluation of age-specific vaccination strategies. Theor Popul Biol 25 125-137.
23. EG Knox (1980) Strategy for rubella vaccination. Int J Epidemiol 9 13-23.
24. RM Anderson, JA Crombie and BT Grenfell (1987) The epidemiology of mumps in the UK: preliminary study of virus transmission, herd immunity and the potential impact of vaccination. Epidemiol Infect 99 65-84.
25. RM May and RM Anderson (1984) Spatial heterogeneity and the design of immunization programmes. Math Biosci 72 83-111.
26. HW Hethcote and JW Van Ark (1987) Epidemiological models for heterogeneous populations: proportionate mixing, parameter estimation, and immunization programs. Math Biosci 84 85-118.
27. BT Grenfell, ON Bjornstad and J Kappey (2001) Travelling waves and spatial hierarchies in measles epidemics. Nature 414 716-723.
28. PM Strebel and SL Cochi (2001) Waving goodbye to measles. Nature 414 695-696.
29. DJ Nokes and RM Anderson (1988) Measles, mumps, and rubella vaccine: what coverage to block transmission? Lancet 2 1374.
30. JA Yorke, N Nathanson, G Pianigiani and J Martin (1979) Seasonality and the requirements for perpetuation and eradication of viruses in populations. Am J Epidemiol 109 103-123.
31. RM Anderson and RM May (1984) Spatial, temporal, and genetic heterogeneity in host populations and the design of immunization programmes. IMA J Math Appl Med Biol 1 233-266.
32. PG Smith, LC Rodrigues and PEM Fine (1984) Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 13 137-153.
33. IM Longini, ME Halloran and A Nizam (2002) Model-based estimation of vaccine effects from community vaccine trials. Stat Med 21 481-495.
34. Assembly World Health (1959) Official Records of the World Health Organization-1959: Resolutions and Decisions of the 12th World Health Assembly (WHA 12.54) Geneva: World Health Organization
35. F Fenner, DA Henderson, I Arita, et al. (1988) Smallpox and Its Eradication Geneva: World Health Organization
36. R Gani and R Leach (2001) Transmission potential of smallpox in contemporary populations. Nature 414 748-751.
37. I Arita, J Wickett and F Fenner (1986) Impact of population density on immunization programmes. J Hyg 96 459-466.
38. DA Henderson (1972) Epidemiology in the global eradication of smallpox. Int J Epidemiol 1 25-30.
39. E Hammerlund, MW Lewis, SG Hansen, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nature Med 9 1131-1137.
40. DA Henderson (1999) The looming threat of bioterrorism. Science 283 1279-1282.
41. M Enserink (2002) How devastating would a smallpox attack really be? Science 297 50-51.
42. AS Fauci (2002) Smallpox vaccination policy-the need for a dialogue. N Engl J Med 346 1319-1320.
43. CP Farrington (1990) Modelling forces of infection for measles, mumps, and rubella. Stat Med 9 953-967.
44. PEM Fine and JA Clarkson (1982) Measles in England and Wales, I. An analysis of factors underlying seasonal patterns. Int J Epidemiol 11 5-14.
45. PEM Fine and JA Clarkson (1982) Measles in England and Wales, II. The impact of the measles vaccination programme on the distribution of immunity in the population. Int J Epidemiol 11 15-25.
46. FL Black (1982) The role of herd immunity in the control of measles. Yale J Biol Med 55 351-360.
47. DJ Sencer, HB Dull and AD Langmuir (1967) Epidemiologic basis for eradication of measles in 1967. Public Health Rep 82 253-256.
48. DR Hopkins, AR Hinman, JP Koplan, et al. (1982) The case for global measles eradication. Lancet 1 1396-1398.
49. DA Henderson (1982) Global measles eradication. Lancet 2 208.
50. World Health Organization (2001) Measles Mortality Reduction and Regional Elimination: Strategic Plan, 2000–2005 (WHO/V&B/01.13) Geneva: World Health Organization
51. CA de Quadros (2004) Can measles be eradicated globally ? Bull WHO 82 134-138.
52. K Fahlgren (1988) Two doses of MMR vaccine-sufficient to eradicate measles, mumps, and rubella? Scand J Soc Med 16 129-135.
53. CA de Quadros, H Izurieta, L Venczel and P Carrasco (2004) Measles eradication in the Americas: progress to date. I Infect Dis 189 S227–S235.
54. M Otten, R Kezaala, A Fall, et al. (2005) Public health impact pf accelerated measles control in the WHO African Region 2000–03. Lancet 366 832-839.
55. Centers for Disease Control and Prevention (2000) Measles, rubella, and congenital rubella syndrome-United States and Mexico, 1997–1999. MMWR 49 1048-1050. 1059
56. N Gay, M Ramsay, B Cohen, et al. (1997) The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep 7 17-21.
57. Panum PL. Observations made during the Epidemic of Measles on the Faroe Islands in the year 1846. Delta Omega Society 1940.
58. H Whittle, P Aaby, B Samb, et al. (1999) Poor serologic responses five to seven years after immunization with high and standard titer measles vaccines. Paediatr Infect Dis J 18 53-57.
59. RM Anderson and RM May (1983) Vaccination against rubella and measles: quantitative investigation of different policies. J Hyg (Camb) 90 259-325.
60. JAM van Druten, T de Boo and AD Plantinga (1986) Measles, mumps, and rubella: control by vaccination. Dev Biol Stand 65 53-63.
61. T Panagiotopoulos, I Antoniadou and E Valassi-Adam (1999) Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 319 1462-1467.
62. K Ueda, Y Nishida, K Oshima, et al. (1978) An explanation for the high incidence of congentital rubella syndrome in Ryukyu. Am J Epidemiol 107 344-351.
63. L Gao and H Hethcote (2006) Simulations of rubella vaccination strategies in China. Math Biosci 202 371-385.
64. HC Meissner, SE Reef and S Cochi (2006) Elimination of rubella from the United States: a milestone on the way to global elimination. Pediatrics 117 933-935.
65. R Kim Farley, S Bart, H Stetler, et al. (1985) Clinical mumps vaccine efficacy. Am J Epidemiol 121 593-597.
66. KM Sullivan, TJ Halpin, JS Marks, et al. (1985) Effectiveness of mumps vaccine in a school outbreak. Am J Dis Child 139 909-912.
67. E Savage, M Ramsay, J White, et al. (2005) Mumps outbreaks across England and Wales in 2004: observational study. Brit Med J 330 1119-1120.
68. JF Seward, BM Watson, CL Peterson and L Mascola (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287 606-611.
69. S Hall, J Sewar, AO Jumaan, et al. (2002) Second varicella infections: are they more common than previously thought? Pediatrics 109 1068-1073.
70. SL Thomas, JG Wheeler and AJ Hall (2002) Contacts with varicella or with children and protection against zoster in adults: a case-control study. Lancet 360 678-682.
71. M Brisson, NJ Gay, WJ Edmunds and NJ Andrews (2002) Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20 2500-2507.
72. GP Garnett and BT Grenfell (1992) The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect 108 513-528.
73. RJ Whitley (2005) Changing dynamics of varicella-zoster virus infections in the 21 st century: the impact of vaccination. J Infect Dis 191 1999-2001.
74. MN Oxman, MJ Levin, GR Johnson, et al. (2005) A vaccine to prevent Herpes zoster and postherpetic neuralgia in older adults. N Eng J Med 352 2271-2284.
75. ME Halloran (1996) Epidemiologic effects of varicella vaccination. Infect Dis Clin North Am 3 631-655.
76. WJ Edmunds and M Brisson (2002) The effect of vaccination on the epidemiology of varicella-zoster virus. J Infect 44 211-219.
77. J Bruer (2005) Varicella vaccination for healthcare workers. Brit Med J 330 433-434.
78. MP Preziosi, A Yam, SG Wassilak, et al. (2002) Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol 155 891-896.
79. B Trollfors, J Taranger, T Lagergard, et al. (1998) Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 17 196-199.
80. PEM Fine and JA Clarkson (1982) The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 2 666-669.
81. BT Grenfell and RM Anderson (1989) Pertussis in England and Wales: an investigation of transmission dynamics and control by mass vaccination. Proc R Soc Lond B Biol Sci 236 213-253.
82. PEM Fine and JA Clarkson (1987) Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 9 866-883.
83. KM Edwards and MD Decker (2004) Pertussis vaccine. Chapter 21. SA Plotkin, WA Orenstein (Eds) Vaccines 4th ed. Philadelphia: Saunders
84. CP Farrington (1992) The measurement of age-specific vaccine efficacy. Int J Epidemiol 21 1014-1020.
85. JD Cherry (1997) The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Dev Biol Stand 89 181-186.
86. PEM Fine (1988) Epidemiological considerations for whooping cough eradication. AL Wardlaw, R Parton (Eds) Pathogenesis and Immunity to Pertussis Chichester, UK: John Wiley 451-467.
87. PEM Fine (1997) Implications of different study designs for the evaluation of acellular pertussis vaccines. Dev Biol Stand 89 123-133.
88. Brown F, Greco D, Mastrantonio P, et al. (eds). Pertussis Vaccine Trials. Dev Biol Stand 89, 1997.
89. PEM Fine (1997) Adult pertussis: a salesman's dream-and an epidemiologist's nightmare. Biologicals 25 195-198.
90. KM Edwards (2001) Is pertussis a frequent cause of cough in adolescents and adults?. Should routine pertussis immunization be recommended. Clin Infect Dis 32 1698-1699.
91. JI Ward, JD Cherry, S-J Chang, et al. (2006) Efficacy of an acellular pertussis vaccine among adolescents and adults. N Eng J Med 353 1555-1563.
92. Committee on Infectious Diseases (2006) Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 117 965-978.
93. CDC. Advisory Committee on Immunization Practice recommends adult vaccination with new tetanus, diphtheria and pertussis vaccine (Tdap). Press release 9 November 2005.
94. LW Miller, JJ Older, J Drake, et al. (1972) Diphtheria immunization: effect upon carriers and the control of outbreaks. Am J Dis Child 123 197-199.
95. EE Jones, RG Kim-Farley, M Algunaid, et al. (1985) Diphtheria: a possible foodborne outbreak in Hodeida, Yemen Arab Republic. Bull World Health Organ 63 287-293.
96. EK Marcuse and MG Grand (1973) Epidemiology of diphtheria in San Antonio, Texas, 1970. JAMA 224 305-310.
97. O Simonson, K Kjeldsen, MW Bentzon and I Heron (1987) Susceptibility to diphtheria in populations vaccinated before and after elimination of indigenous diphtheria in Denmark. Acta Pathol Microbiol Immunol Scand 95 225-231.
98. GM McQuillan, D Kruszon-Moran, A Deforest, et al. (2002) Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 136 660-666.
99. PA Maple, CS Jones, EC Wall, et al. (2000) Immunity to diphtheria and tetanus in England and Wales. Vaccine 19 167-173.
100. B Christenson, U Hellstrom, SP Sylvan, et al. (2000) Impact of a vaccination campaign on adult immunity to diphtheria. Vaccine 19 1133-1140.
101. RT Chen, CV Broome, RA Weinstein, et al. (1985) Diphtheria in the United States, 1971–1981. Am J Public Health 75 1393-1397.
102. JA Doull and H Lara (1925) The epidemiologic importance of diphtheria carriers. Am J Hyg 5 508-529.
103. M Bergamini, P Fabrizi, S Pagani, et al. (2000) Evidence of increased carriage of Corynebacterium spp. in healthy individuals with low antibody titres against diphtheria toxoid. Epidemiol Infect 125 105-112.
104. ER Moxon and P Anderson (1979) Meningitis caused by Haemophilus influenzae in infant rats: protective immunity and antibody priming by gastrointestinal colonization with Escherichia coli. J Infect Dis 140 471-478.
105. R Dagan, D Fraser, M Roitman, et al. (1998) Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. Vaccine 17 134-141.
106. RA Adegbola, O Secka, G Lahai, et al. (2005) Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with Hib conjugate vaccine: a prospective study. Lancet 366 144-150.
107. H Peltola, P Aavitsland, KG Hansen, et al. (1999) Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 179 223-229.
108. CL Trotter, ME Ramsay and MPE Slack (2003) Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Pub Hlth 6 55-58.
109. A Soininen, H Pursiainen, T Kilpi and H Kayhty (2001) Natural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young children. J Infect Dis 184 569-576.
110. MH Kyaw, R Lynfield, W Schaffner, et al. (2006) Effect of introduction of the pneumococcal vaccine on drug resistant Streptococcus pneumoniae. N Eng J Med 354 1455-1463.
111. RJ Singleton, TW Hennessy, LR Bulkow, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 1784-1792.
112. DM Musher (2006) Pneumococcal vaccine—direct and indirect (‘herd’) effects. N Eng J Med 354 1522-1524.
113. FT Cutts, SM Zaman, G Enwere, et al. (2005) Efficacy of nine-valent pneumococcal vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet 365 1139-1146.
114. KW Newell, A Duenas Lehman, DR LeBlanc, et al. (1966) The use of toxoid for the prevention of tetanus neonatorum: final report of a double-blind controlled field trial. Bull World Health Organ 35 863-871.
115. JL Melnick (1978) Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ 56 21-38.
116. PEM Fine and IAM Carneiro (1999) Transmissibility and persistence of oral polio vaccine viruses. Am J Epidemiol 150 1001-1021.
117. BM Nkowane, SGF Wassilak, WA Orenstein, et al. (1987) Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA 257 1335-1340.
118. M Bottiger (1987) A study of the sero-immunity that has protected the Swedish population against poliomyelitis for 25 years. Scand J Infect Dis 19 595-601.
119. T Hovi, K Cantell, A Huovilainen, et al. (1986) Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1 1427-1432.
120. GJ Schaap, H Bijkerk and RA Coutinho (1984) The spread of wild polio virus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 29 124-140.
121. OM Kew, RW Sutter, E de Gourville, et al. (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradiction. Annu Rev Microbiol 59 587-635.
122. Centers for Disease Control and Prevention (2005) Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 54(RR08), 1-40.
123. AS Monto, FM Davenport, JA Napier, et al. (1970) Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 22 16-25.
124. LG Rudenko, AN Slepushkin, AS Monto, et al. (1993) Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 168 881-887.
125. WP Glezen (2006) Herd protection against influenza. J Clin Virol 37 237-243.
126. JC King Jr, JJ Stoddard, MJ Gaglani, et al. (2006) Effectiveness of school-based influenza vaccination. N Eng J Med 355 2423-2432.
127. TA Reichert, N Sugaya, DS Fedson, et al. (2001) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344 889-896.
128. ME Halloran, PA Piedra, IM Longini Jr, et al. (2007) Efficacy of trivalent, cold adapted influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003–2004. Vaccine 25 4038-4045.
129. NM Ferguson, DAT Cummings, S Cauchemez, et al. (2006) Strategies for mitigating an influenza pandemic. Nature 442 448-452.
130. IM Longini, A Nizam, S Xu, et al. (2005) Containing pandemic influenza at source. Science 309 1083-1087.
131. IM Longini and ME Halloran (2005) Strategy for distribution of influenza vaccine to high risk groups and children. Am J Epidemiol 161 303-306.
132. LL Villa, RLR Costa, CA Petta, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L! virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 271-278.
133. GP Garnett (2005) Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Inf Dis 191(Suppl 1), S97–S106.
134. EJ Dasbach, EH Elbasha and RP Insinga (2006) Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiologic Reviews 28 88-100.
135. A Kochi, P Nunn, C Dye and E Tayler (1997) Global burden of disease. Lancet 350 142.
136. PEM Fine, IAM Carneiro, JB Milstein and CJ Clements (1999) Issues Relating to the Use of BCG in Immunization Programmes (WHO/V&B/99.23) Geneva: World Health Organization
137. PEM Fine, JAC Sterne, JM Ponnighaus and RJW Rees (1994) Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet 344 1245-1249.
138. K Styblo and J Meijer (1976) Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 57 17-43.
139. NE Aronson, M Santosham, GW Comstock, et al. (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. J Am Med Assoc 291 2086-2091.
140. I Sutherland and I Lindgren (1979) The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 60 225-231.
141. A Soysal, KA Millington, M Bakir, et al. (2005) Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366 1443-1451.
142. BB Trunz, PEM Fine and C Dye (2006) Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a metaanalysis nd assessment of cost-effectiveness. Lancet 367 1175-1182.
143. PEM Fine (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 1339-1345.
144. PEM Fine and E Vynnycky (1998) The effect of heterologous immunity upon the apparent efficacy of (eg BCG) vaccines. Vaccine 16 1923-1928.
145. S Brooker, JM Bethony, LC Rodrigues, et al. (2005) Epidemiologic, immunologic and practical considerations in developing and evaluating a human hookworm vaccine. Expert Rev Vaccines 4 35-50.
146. MF Good, H Xu, M Wykes, et al. (2005) Development ond regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Ann Rev Immunol 23 69-99.
147. ME Halloran, M Haber, IM Longini and CJ Struchiner (1991) Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 133 323-331.
148. G Bjune, EA Hoiby, JK Gronnesby, et al. (1991) Effects of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338 1093-1096.
149. M Ali, M Emch, L von Seidlin, et al. (2005) Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 44-49.
150. TJ John and R Samuel (2000) Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 16 6–1-606.
151. LE Klock and GS Rachelefsky (1973) Failure of rubella herd immunity during an epidemic. N Engl J Med 288 69-72.
152. WA Orenstein and AR Hinman (1999) The immunization system in the United States-the role of school immunization laws. Vaccine 17(Suppl), S19-S24.